JJJoseph Jankovic

Joseph Jankovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joseph Jankovic has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial

    by Robert E. Wharen, Michael S. Okun, Barton L. Guthrie, Ryan J. Uitti, Paul Larson, Kelly Foote, Harrison Walker, Frederick J. Marshall, Jason Schwalb, Blair Ford, et al.


  • Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia

    by Dhanya Vijayakumar, Joseph Jankovic

    Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly chorea, dystonia, stereotypies, and akathisia. The main types of drug-induced dyskinesias include levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease and tardive syndrome (TS), typically present in patients with psychiatric or gastrointenstinal disorders treated with dopamine receptor blocking drugs, also referred to as neuroleptics. Besides preventive measures (i.e., avoiding the use of the offending drugs), general treatment strategies include slow taper of the offending agent and use of dopamine-depleting agents like tetrabenazine. Botulinum toxin may be helpful for wearing off focal dystonia and some forms of tardive dystonia. Deep brain stimulation is usually reserved for patients with disabling motor fluctuations, LID, and for severe TS that cannot be managed medically.


  • Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia

    by Dhanya Vijayakumar, Joseph Jankovic

    Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly chorea, dystonia, stereotypies, and akathisia. Levodopa-induced dyskinesia (LID) is one of the main types of drug-induced dyskinesia, occurring in patients with Parkinson’s disease (PD) who have been treated with levodopa for long time, but this side effect may be encountered even within a few weeks or months after initiation of levodopa therapy. Based on the temporal pattern in relationship to levodopa dosing, LIDs are divided into “peak-dose dyskinesia,” “diphasic dyskinesia,” and “wearing off” or “off-period” dyskinesia, of which peak-dose dyskinesia is the most common, followed by off-period, and then diphasic dyskinesia. Treatment strategy includes identifying the kind of dyskinesia and tailoring treatment accordingly. Peak-dose dyskinesia is treated mainly by reducing individual doses of levodopa and adding amantadine and dopamine agonists, whereas off-period dystonia often responds to baclofen and botulinum toxin injections. Diphasic dyskinesias, occurring particularly in patients with young-onset PD, are the most difficult to treat. While fractionation of levodopa dosage is the most frequently utilized strategy, many patients require deep brain stimulation to control their troublesome motor fluctuations and LIDs. A variety of emerging (experimental) drugs currently in development promise to provide better control of LIDs and other levodopa-related complications in the near future.


  • Myorhythmia: Phenomenology, etiology, and treatment

    by José Fidel Baizabal‐Carvallo, Francisco Cardoso, Joseph Jankovic

    Myorhythmia is defined as repetitive, rhythmic, slow (1‐4 Hz) movement affecting chiefly cranial and limb muscles. When occurring in the limbs it may be oscillatory and jerky, whereas oculo‐masticatory myorhythmia, typically associated with Whipple's disease, is a slow, repetitive, often asymmetrical, facial and ocular movement. Thus, myorhythmia overlaps phenomenologically with tremor and segmental myoclonus. Although often present at rest, it must be differentiated from parkinsonian or dystonic tremor. Recognition of this movement disorder is important because it is usually associated with lesions involving the brainstem, thalamus, or other diencephalic structures with potentially treatable etiologies. In addition to Whipple's disease, myorhythmia has been described in patients with cerebrovascular disease, listeria encephalitis, anti‐N‐methyl‐d‐aspartate receptor encephalitis, steroid‐responsive encephalopathy associated with autoimmune thyroiditis, multiple sclerosis, and other disorders. In addition to our own experience, we have systematically reviewed the medical literature, focusing on the phenomenology, pathophysiology, and etiology of this poorly recognized movement disorder. In this review, we aim to highlight the clinical features that differentiate myorhythmia from other movement disorders. Treatment should be directed against the underlying etiology. © 2014 International Parkinson and Movement Disorder Society


  • The spectrum of movement disorders in children with anti‐NMDA receptor encephalitis

    by José Fidel Baizabal‐Carvallo, Amber Stocco, Eyal Muscal, Joseph Jankovic

    Background: Movement disorders are frequent but difficult to characterize in patients with anti‐N‐methyl‐d‐aspartate receptor (NMDAR) encephalitis.Methods: The phenomenology of movement disorders was characterized after a detailed examination of children with anti‐NMDAR‐encephalitis.Results: We studied 9 children (5 females), ages 3–14 years, with confirmed anti‐NMDAR‐encephalitis. All patients presented with at least 1 movement disorder, including chorea (n=4), stereotypic movements (n=4), ataxia (n=3), limb dystonia (n=2), limb myorhythmia (n=2), oromandibular dystonia (n=2), facial myorhythmia, blepharospasm, opisthotonus, athetosis, and tremor (n=1, each). More than a single movement disorder was observed in 6 of these patients. Resolution of the abnormal movements was observed in all patients with immunotherapy; 1 patient improved with tetrabenazine.Conclusions: A wide variety of movement disorders, often in combination, can be observed in children with anti‐NMDAR encephalitis. Patients commonly present with more than a single movement disorder. © 2013 Movement Disorder Society


  • Respiratory disorders associated with dystonia

    by Raja Mehanna, Joseph Jankovic

    Background: Respiratory difficulties are sometimes reported by patients with cranial‐cervical and other forms of dystonia, but the nature or mechanisms of the breathing problems have not been well characterized.Case Report: We review 13 dystonic patients with various respiratory complaints and describe their symptoms and response to treatment, including botulinum toxin (BoNT) injections.Discussion: Gasping, stridor, interrupted flow of speech, paradoxical breathing, dyspnea on exertion, and other respiratory symptoms reported by patients suggest involvement of the upper airways, chest, and diaphragm. BoNT injections may be, at least partially, beneficial in some patients.Conclusion: This series of patients draws attention to respiratory distress as a potentially serious, even life‐threatening, complication of dystonia. © 2012 Movement Disorder Society


  • Open Access

    Effect of Tetrabenazine on Motor Function in Patients with Huntington Disease

    by Joseph M. Ferrara, Giovanni Mostile, Christine Hunter, Octavian R. Adam, Joseph Jankovic

    Introduction Tetrabenazine (TBZ) reduces chorea related to Huntington disease (HD); however, it is uncertain whether this effect improves functionally relevant motor skills such as hand coordination and balance. The objective of this study was to provide pilot data regarding three motor function tests, which might be useful in monitoring symptom progression and therapeutic response, pending formal validation. Methods The authors assessed 11 ambulatory patients with HD-related chorea on two occasions: (1) while off TBZ (either prior to starting therapy or following a >24 h washout) and (2) when on a stable dose of TBZ, titrated to optimal effect. Study evaluations included the Jebsen-Taylor Hand Function Test (JTHFT) and Berg Balance Scale, a timed 25-foot walk, the Montreal Cognitive Assessment (MoCA) and the complete United Huntington Disease Rating Scale (UHDRS). Results Maximal chorea scores (UHDRS item 12) improved from 11.1 ± 2.9 to 8.5 ± 3.9 while on TBZ (P = 0.03), but we could not detect an improvement in functional measures while on TBZ in this small cohort. Scores of the JTHFT were globally slower than published normative data and correlated with MoCA summary scores, but not UHDRS chorea scores. Conclusions This pilot study did not detect significant functional gains with chorea suppression. The fact that performance on tests of hand function correlates with MoCA but not UHDRS chorea scores highlights the need for additional treatments targeted toward the cognitive aspects of HD.


  • Movement disorders in autoimmune diseases

    by Baizabal‐ Carvallo, José Fidel, Joseph Jankovic

    Movement disorders have been known to be associated with a variety of autoimmune diseases, including Sydenham's chorea, pediatric autoimmune neuropsychiatric disorders associated with streptococcus, systemic lupus erythematosus, antiphospholipid syndrome, gluten sensitivity, paraneoplastic and autoimmune encephalopathies. Tremors, dystonia, chorea, ballism, myoclonus, parkinsonism, and ataxia may be the initial and even the only presentation of these autoimmune diseases. Although antibodies directed against various cellular components of the central nervous system have been implicated, the pathogenic mechanisms of these autoimmune movement disorders have not yet been fully elucidated. Clinical recognition of these autoimmune movement disorders is critically important as many improve with immunotherapy or dietary modifications, particularly when diagnosed early. We discuss here the clinical features, pathogenic mechanisms, and treatments of movement disorders associated with autoimmune diseases, based on our own experience and on a systematic review of the literature. © 2012 Movement Disorder Society